tetano
Editor, Senior Moderator
Vaccine. 2017 Feb 8. pii: S0264-410X(17)30061-0. doi: 10.1016/j.vaccine.2017.01.026. [Epub ahead of print]
[h=1]Evaluation of multivalent H2 influenza pandemic vaccines in mice.[/h] Lenny BJ[SUP]1[/SUP], Sonnberg S[SUP]2[/SUP], Danner AF[SUP]2[/SUP], Friedman K[SUP]2[/SUP], Webby RJ[SUP]2[/SUP], Webster RG[SUP]2[/SUP], Jones JC[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Subtype H2 Influenza A viruses were the cause of a severe pandemic in the winter of 1957. However, this subtype no longer circulates in humans and is no longer included in seasonal vaccines. As a result, individuals under 50years of age are immunologically na?ve. H2 viruses persist in aquatic birds, which were a contributing source for the 1957 pandemic, and have also been isolated from swine. Reintroduction of the H2 via zoonotic transmission has been identified as a pandemic risk, so pre-pandemic planning should include preparation and testing of vaccine candidates against this subtype. We evaluated the immunogenicity of two inactivated, whole virus influenza vaccines (IVV) in mice: a monovalent IVV containing human pandemic virus A/Singapore/1/1957 (H2N2), and a multivalent IVV containing human A/Singapore/1/1957, avian A/Duck/HongKong/319/1978 (H2N2), and swine A/Swine/Missouri/2124514/2006 (H2N3) viruses. While both vaccines induced protective immunity compared to na?ve animals, the multivalent formulation was advantageous over the monovalent in terms of level and breadth of serological responses, neutralization of infectious virus, and reduction of clinical disease and respiratory tissue replication in mice. Therefore, multivalent pandemic H2 vaccines containing diverse viruses from animal reservoirs, are a potential option to improve the immune responses in a pre-pandemic scenario where antigenic identity cannot be predicted.
Copyright ? 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] H2N2; Influenza; Monovalent; Multivalent; Pandemic; Vaccine
PMID: 28189402 DOI: 10.1016/j.vaccine.2017.01.026
[PubMed - as supplied by publisher]
[h=1]Evaluation of multivalent H2 influenza pandemic vaccines in mice.[/h] Lenny BJ[SUP]1[/SUP], Sonnberg S[SUP]2[/SUP], Danner AF[SUP]2[/SUP], Friedman K[SUP]2[/SUP], Webby RJ[SUP]2[/SUP], Webster RG[SUP]2[/SUP], Jones JC[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Subtype H2 Influenza A viruses were the cause of a severe pandemic in the winter of 1957. However, this subtype no longer circulates in humans and is no longer included in seasonal vaccines. As a result, individuals under 50years of age are immunologically na?ve. H2 viruses persist in aquatic birds, which were a contributing source for the 1957 pandemic, and have also been isolated from swine. Reintroduction of the H2 via zoonotic transmission has been identified as a pandemic risk, so pre-pandemic planning should include preparation and testing of vaccine candidates against this subtype. We evaluated the immunogenicity of two inactivated, whole virus influenza vaccines (IVV) in mice: a monovalent IVV containing human pandemic virus A/Singapore/1/1957 (H2N2), and a multivalent IVV containing human A/Singapore/1/1957, avian A/Duck/HongKong/319/1978 (H2N2), and swine A/Swine/Missouri/2124514/2006 (H2N3) viruses. While both vaccines induced protective immunity compared to na?ve animals, the multivalent formulation was advantageous over the monovalent in terms of level and breadth of serological responses, neutralization of infectious virus, and reduction of clinical disease and respiratory tissue replication in mice. Therefore, multivalent pandemic H2 vaccines containing diverse viruses from animal reservoirs, are a potential option to improve the immune responses in a pre-pandemic scenario where antigenic identity cannot be predicted.
Copyright ? 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] H2N2; Influenza; Monovalent; Multivalent; Pandemic; Vaccine
PMID: 28189402 DOI: 10.1016/j.vaccine.2017.01.026
[PubMed - as supplied by publisher]